Skip to content

Study · Animal study (in vivo) · mouse · 2018

5 results

Novel GLP-1/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice.

Wismann P, Pedersen SL, Hansen G, Mannerstedt K, Pedersen PJ, Jeppesen PB, Vrang N, Fosgerau K, Jelsing J

Physiology & behavior11 Mar 2018Cited by 34 (Europe PMC)

PMID29540315 (opens in a new tab)DOI10.1016/j.physbeh.2018.03.004 (opens in a new tab)PepBankPUB-29540315
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In lean mice, food intake was higher with teduglutide monotherapy than with GUB09-123.

    In plain wordsIn mice, food intake was higher with teduglutide alone than with GUB09-123.

    Peptide
    Teduglutide
    Outcome
    IncreaseFood intake versus co-agonist
    Study

    mousen: not reported in source

    Lean mice
    Comparator
    GUB09-123
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · Sub-chronicAs given in this study (mouse).

    Source sentences

    Summary
    Sub-chronic administration of GUB09-123 to lean mice significantly reduced food intake, improved glucose tolerance, and increased gut volume, superior to monotherapy with the GLP-2 analogue teduglutide.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In lean mice, glucose tolerance was worse with teduglutide monotherapy than with GUB09-123.

    In plain wordsIn mice, glucose tolerance was worse with teduglutide alone than with GUB09-123.

    Peptide
    Teduglutide
    Outcome
    DecreaseGlucose tolerance versus co-agonist
    Study

    mousen: not reported in source

    Lean mice
    Comparator
    GUB09-123
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · Sub-chronicAs given in this study (mouse).

    Source sentences

    Summary
    Sub-chronic administration of GUB09-123 to lean mice significantly reduced food intake, improved glucose tolerance, and increased gut volume, superior to monotherapy with the GLP-2 analogue teduglutide.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In lean mice, gut volume was lower with teduglutide monotherapy than with GUB09-123.

    In plain wordsIn mice, gut volume was lower with teduglutide alone than with GUB09-123.

    Peptide
    Teduglutide
    Outcome
    DecreaseGut volume versus co-agonist
    Study

    mousen: not reported in source

    Lean mice
    Comparator
    GUB09-123
    Outcome group
    Gut Growth · Gastrointestinal
    Studied dose
    Dose not stated · Sub-chronicAs given in this study (mouse).

    Source sentences

    Summary
    Sub-chronic administration of GUB09-123 to lean mice significantly reduced food intake, improved glucose tolerance, and increased gut volume, superior to monotherapy with the GLP-2 analogue teduglutide.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, glycemic control was worse with liraglutide monotherapy than with GUB09-123.

    In plain wordsIn diabetic mice, blood glucose control was worse with liraglutide alone than with GUB09-123.

    Peptide
    Liraglutide
    Outcome
    DecreaseGlycemic control versus co-agonist
    Study

    mousen: not reported in source

    Diabetic db/db mice
    Comparator
    GUB09-123
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · ChronicAs given in this study (mouse).

    Source sentences

    Summary
    Chronic administration of GUB09-123 to diabetic mice significantly improved glycemic control and showed persistent effects on gastric emptying, superior to monotherapy with the GLP-1 analogue liraglutide.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, liraglutide monotherapy had inferior gastric-emptying effects to the persistent effects reported for GUB09-123.

    In plain wordsIn diabetic mice, liraglutide had weaker gastric-emptying effects than GUB09-123.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedGastric emptying versus co-agonist
    Study

    mousen: not reported in source

    Diabetic db/db mice
    Comparator
    GUB09-123
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    Dose not stated · ChronicAs given in this study (mouse).

    Source sentences

    Summary
    Chronic administration of GUB09-123 to diabetic mice significantly improved glycemic control and showed persistent effects on gastric emptying, superior to monotherapy with the GLP-1 analogue liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 2

    27 Oct 2026, 16:37 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.